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1. Introduction 
Autologous stem cell transplantation (ASCT) is used for disease stabilization and 
improvement of performance status in patients with immunoglobulin light chain 
amyloidosis. This therapeutic strategy has a relatively high treatment-related mortality. 
Therefore the limited treatment efficiency (cure is not possible) versus the risk of severe 
toxicity must be considered in each individual patient. The treatment-related mortality 
(TRM) has been up to 24% (Jaccard et al., 2007) and even 70% in certain studies (Moreau et 
al., 1998), but mostly lower mortality is reported (Vesole et al., 2006). These differences are 
probably due to patient selection criteria because TRM seems, among the other factors, to be 
associated mainly with cardiac amyloidosis. However, two main questions need to be 
answered with regard to efficiency versus toxicity of ASCT in amyloidosis. Firstly, one 
would appraise ASCT to be an effective treatment also in patients with cardiac amyloidosis, 
and ASCT could be considered also for these patients if the risk of severe toxicity could be 
reduced. Secondly, it can be difficult to select patients without cardiac amyloidosis for ASCT 
due to some uncertainity in assessment of cardiac involvement.  
Determination of cardiac involvement is routinely performed by echocardiography despite the 
fact that the sensitivity of echocardiography is limited. Endomyocardial biopsy provides 
more reliable diagnosis but is associated with 1-2% complications (Cooper et al., 2007; 
Yilmaz et al., 2010). Thus, increased safety for patients with cardiac involvement may also 
reduce the risk of severe toxicity for patients without detectable cardiac involvement.  
Dimethyl sulfoxide (DMSO) is used for cryopreservation of the stem cell autografts and the 
amount of DMSO infused together with the transplant may probably contribute to the early 
TRM in patients with amyloidosis. Several reports have described fatal outcome of autograft 
infusion, especially in patients with cardiac amyloidosis (Saba et al., 1999; Zenhäusern et al., 
2000). By reducing the amount of infused DMSO, it may be possible to reduce the risk of 
ASCT-associated mortality and thereby make this treatment available for additional 
patients. In this chapter we will review various strategies that can be used to reduce the 
amount of DMSO infused together with autologous stem cell grafts.  
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2. Autologous stem cell transplantation in primary systemic amyloidosis 
Primary systemic amyloidosis (AL) is a serious disease with a short survival (12-18 months) 
when conventional treatment with melphalan and prednisone is given (Dispenzeri et al., 
2001). Patients with manifest cardiac involvement, being the worst prognostic indicator 
(Dubrey et al., 1998), have even poorer prognosis and a shorter survival; 4-6 months. 
Cardiac involvement is seen approximately in 50% of patients and half of them have 
congestive heart failure (Eshaghian et al., 2007). Arrhythmias and/or heart failure are the 
most frequent reasons of death in these patients.  
Autologous stem cell transplantation is performed for disease stabilization and 
improvement of performance status in eligible AL patients. However, this therapeutic 
strategy has a high TRM; 15% to 70%, depending mostly on the patient selection criteria; 
meaning multiorgan involvement and especially advanced cardiac amyloidosis (Skinner et 
al., 2004; Moreau et al., 1998). Considering that TRM is less than 4% for patients with 
multiple myeloma (Segeren et al., 2003), even the lowest reported 15% TRM is unacceptably 
high for AL pateints. Therefore, patient selection for transplantation is a key issue (Tichelli 
et al., 2008). Underdiagnosed cardiac involvement may also be assumed to be an underlying 
factor in the high early TRM. DMSO used for cryopreservation of the stem cell autografts, is 
a cardiotoxic agent, and when infused together with the transplant DMSO may contribute to 
the treatment-related toxicity in AL patients. Several case reports have described fatal 
outcome of autograft infusion, especially in patients with cardiac amyloidosis (Saba et al., 
1999; Zenhäusern et al., 2000). Severe arrhythmias including atrial fibrillation are reported in 
the early stage of transplantation. Reduction of complications related to stem cell infusion 
may be achieved by different strategies for decreasing the amount of DMSO in the infused 
autologous stem cell grafts, since DMSO reduction may in turn promote/endorse 
improvement of early phase survival in AL patients. 
3. Cardiac involvement in primary amyloidosis 
Cardiac involvement is quite often in AL amyloidosis, occurring in up to 63 percent of the 
patients (Merlini et al., 2008). Symptoms are related to the localization and the degree of the 
amyloid accumulation in the heart. Since cardiac involvement that may result in congestive 
heart failure is rapidly fatal, it is important to realize the condition and choose the right 
treatment option as soon as possible.  
Assessment of heart involvement is mostly made by evaluation of the clinical symptoms, 
electrocardiography (ECG), detection of biomarkers N terminal Pro brain natriuretic peptide 
(NT-proBNP) and troponins, scintigraphy, echocardiography, magnetic resonance imaging 
(MRI) and/or endomyocardial biopsy. Except for the latter method all the assessments are 
non-invasive. Low voltage, arrhythmias and conduction abnormalities may be found in 
ECG (Eshaghian et al., 2007). The biomarkers are sensitive markers of heart damage, but 
they are not specific for damage caused by amyloid light chains. NT-proBNP was reported 
to be very valuable in diagnosis of ventricular dysfunction (Krishnaswamy et al., 2001), in 
assessing prognosis of heart failure and after myocardial infarction (Palladini et al., 2003). In 
one study, NT-proBNP appeared to be more sensitive than conventional echocardiographic 
parameters in detecting clinical improvement or worsening of amyloid cardiomyopathy 
during follow-up, meaning that NT-proBNP is a powerful prognostic determinant in AL 
amyloidosis (Palladini et al., 2003) and not necessarily diagnostic. However, as mentioned 
above high values of NT-ProBNP and cardiac troponins are seen also in other cardiac 
diseases like coronary artery disease and atrial fibrillation. NT-ProBNP is elevated as a 
www.intechopen.com
Autologous Stem Cell Transplantation in the Treatment of Amyloidosis –  
Can Manipulation of the Autograft Reduce Treatment-Related Toxicity? 
 
187 
result of left ventricular dysfunction in congestive heart failure. On the other hand, a normal 
NT-ProBNP can be used to eliminate myocardial amyloidosis. 
Scintigraphy with various tracers has some value in diagnosis; either with technetium  
99 m-pyrophosphate to differentiate AL amyloidosis from other transthyretin-associated 
amyloidosis or with I123-labeled serum amyloid P (Hazenberg et al., 2006). Increased 
interventricular septum thickness and “granular sparkling” of the myocardium at 
echocardiography is helpful but not specific and sensitive enough. Increased myocardial 
echogenity and valve-thickening are also frequent findings by echocardiography (Dubrey et 
al., 1998). Late gadolinium enhancement-cardiac MRI may detect early cardiac abnormalities 
in patients with amyloidosis with normal left ventricular thickness (Syed et al., 2010). 
Finally, demonstration of amyloidosis by endomyocardial biopsy confirms the diagnosis in 
a patient whose echocardiography shows a mean left ventricular wall thickness more than 
12 mm, when no other cardiac cause can be identified (Gertz et al., 2004). Tissue biopsies 
from other organs than the heart, showing amyloid deposits are not diagnostic for cardiac 
amyloidosis (Eshaghian et al., 2007). On the other hand, the endomyocardial biopsy being a 
diagnostic, yet invasive method may be associated with complications like bleeding, 
arrhythmias, thrombosis, infection, injury to the recurrent laryngeal nerve, heart block, injury 
to the vein/artery of the catheterization, pneumothorax and tricuspid regurgitation due to 
damage to the valve. Another seldom complication can be the rupture of the heart with 
pericardial tamponade (Cooper et al., 2007; Yilmaz et al., 2010). Complication rates vary 
between  0.6 and 6 percent (Cooper et al., 2007; Yilmaz et al.; 2010), and the frequency of the 
complications depends on various factors including the experience of the operator, clinical 
status of the patient, and presence or absence of left bundle-branch block (Cooper et al.; 2007). 
4. Adverse effects related to stem cell infusion 
In allogeneic stem cell transplantation setting, allografts harvested from healthy donors are 
usually infused to patients freshly. Autologous stem cell grafts, however, must be 
cryopreserved because of the time needed for in vitro quality controls (e.g. aerobic and 
anaerobic bacterial cultures, CD34+ cell enumeration and/or colony-forming unit assays) of 
the grafts and administration of high-dose chemotherapy before stem cell infusion. 
Autografts are commonly stored in nitrogen tanks at minus 160-180°C after controlled-rate 
freezing either on the harvesting day or the day after. Various controlled-rate freezers 
provide gentle cooling by -1 to -2ºC/min to about -40 to -50ºC, thereafter -5 to -10ºC/min to 
about -80 to -90ºC/min. At this point some centres transfer the bags to nitrogen tanks for 
storage, others continue the controlled-rate freezing until the temperature is equivalent to 
the nitrogen containers’. Despite the fact that liquid phase of nitrogen provides more stable 
temperature for storage, higher risk of contamination from other bags is documented and 
vapor phase appears consequently to be safer (Fountain et al.; Tedder et al., 1995). 
Cryoprotectants prevent intracellular formation of ice crystals that can damage cellular 
structures, and are therefore added to autografts before freezing (Szmant, 1975). The most 
commonly used cryoprotectant is DMSO, which is associated with well-known adverse 
effects during and shortly after autograft infusion, corresponding to the early 
transplantation stage. Besides DMSO itself, the adverse effects can also be due to DMSO-
induced histamine release, and cell debris/lysis products released by graft white blood cells 
(WBCs) (Calmels et al., 2007; Milone et al., 2007; Saur-Heilborn et al., 2004). The frequency 
and severity of the adverse effects seems to increase with the amount of infused DMSO 
(Halle et al. 2001; Stroncek et al., 1991; Zambelli et al. 1998), a high number of granulocytes 
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in the autograft (Cordoba et al., 2007), and a high patient age (Milone et al., 2007). Mild 
adverse reactions like transient nausea, vomiting, headache, flushing, chest tightness, 
hypotension, bradycardia, and abdominal cramps are common (Alessandrino et al., 1999; 
Donmez et al., 2007; Zambelli et al. 1998), whereas serious reactions like hypertension, 
arrhythmias, cardiac arrest, anaphylaxis, respiratory arrest, multiorgan failure, and neurologic 
complications are rare (Bauwens et al., 2005; Chen-Plotkin et al., 2007; Nishihara et al., 1996; 
Hentschke et al., 2006). The risk of DMSO-associated fatal complications, however, is 
increased for certain diseases, for example, primary amyloidosis (Benekli et al., 2000; Saba et 
al., 1999; Zenhäusern et al., 2000). 
5. Reduction of infused DMSO 
Infusion of lesser DMSO may improve the treatment-related mortality in primary 
amyloidosis patients, especially in the early transplantation period. There are several 
methods of reducing the amount of infused DMSO and consequently decreasing the risk of 
adverse effects in association with stem cell infusion: 
5.1 Reduction of the autograft volume and increasing the cell concentration 
Increasing the cell concentration in the autograft and thereby reducing both the autograft 
volume and the amount of DMSO needed for cryopreservation is a simple strategy 
(Cabezudo et al., 2000; Martin-Henao et al., 2005; Rowley et al., 1994). The final mononuclear 
cell concentration in the autografts varies between transplantation centers; the most 
common concentration being 2 × 108/mL (Windrum et al., 2005). Some centres use higher 
and some use lower concentrations (for example 1 × 108/mL), whilst others do not have any 
limits (Windrum et al., 2005). Several reports describe cryopreservation with high cell 
concentrations not resulting in additional loss of hematopoietic progenitor cell function, and 
not impairing the hematopoietic reconstitution (Cabezudo et al., 2000; Rowley et al., 1994), 
despite lower viability in samples with high concentration; 0.9 (range: 0.6-1) versus 2.9 
(range: 2.2-4.7) × 108/mL (Cabezudo et al., 2000). 
Reduction of the autograft volume by centrifugation prior to cryopreservation of the stem 
cells, as we performed, results in lower autograft volumes that will consequently require 
reduced amounts of DMSO for cryopreservation (Akkok et al., 2009). Cell concentration 
before freezing was kept at minimum 2 × 108/mL in our study. We could therefore report 
low frequencies of side effects in our patients who also received DMSO-depleted autografts, 
since we followed a combination strategy with both volume reduction and DMSO-depletion 
procedure (the latter method will be explained detailed in 5.4) (Akkok et al., 2009).  
5.2 Infusion of autografts over longer time 
Infusion of autografts over longer time, if necessary several days (Martino et al., 1996), will 
reduce the daily DMSO exposure and limit the toxicity. The necessity is due to large volumes 
of the autografts to be returned to the patients. Patients in whom stem cell harvesting has to 
be performed in several subsequent days or patients who have to be re-mobilized usually 
have larger autograft volumes. Approximately 60% (57 out of 97 centres) of the European 
Group for Blood and Marrow Transplantation (EBMT) transplantation centres that replied a 
questionnaire, which was performed to assess current practice in the use of DMSO, had an 
upper limit in the amount of DMSO given per day varying between 20 to 80g (Windrum et 
al., 2005). Among the other centres the most frequently used limit was 1g/kg/day (33 out  
of 97 centres) or the centres did not have an upper limit of DMSO given per day. 
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Approximately one third of the centres preferred to return cells in split doses (Windrum et 
al., 2005). This study reveals the fact that there are no guidelines or agreement on the daily 
maximum dose of DMSO expected to be tolerated rather safely of the patients. In our study, 
when the total autograft volume exceeded 500 mL (i.e., total DMSO amount >50 mL for 
unmanipulated grafts), the stem cell infusion was divided into two separate sessions with at 
least a 2-hour interval or two subsequent days (Akkok et al., 2009). 
5.3 Using DMSO concentrations lower than 10 percent  
Using DMSO concentrations lower than 10 percent reduces complication rate (Akkok et al., 
2009; Curcoy et al., 2002; Galmes et al., 2007; Windrum et al., 2005). There are only a few 
clinical studies where DMSO is used as the sole cryoprotectant at a 5 percent or lesser 
concentration (Akkok et al., 2009; Curcoy et al., 2002; Galmes et al. 1996, 2007). One other 
group used 3.5% DMSO, which is the lowest reported DMSO concentration in a clinical study 
but it was used in combination with 2.5% hydroxyethyl starch and followed by storage at -
80°C (Halle et al., 2001). Galmés and colleagues, on the other hand, reported cryopreservation 
using only 5% DMSO and promptly hematopoietic engraftment as expected after short-time 
storage but slower hematopoietic recovery following long-time storage at -80°C (Galmes et 
al., 1996, 1999, 2007). Nevertheless, hematopoietic reconstitution was similar in both groups, 
when the patients were transplanted with more than 1.5 × 106/kg CD34+ cells (Galmes et al., 
2007). In addition, they showed reduced infusion-related toxicity (19% versus 6.8%) 
compared to 10 % DMSO. However, the authors do not recommend storage of grafts at -
80°C for longer than 6 months due to progressively diminishing viability of mononuclear 
cells (MNC) and recovery rates of colony-forming units; granulocyte-macrophage (CFU-
GM) and burst-forming unit erythroid (BFU-E) reaching zero after 24 months, when grafts 
are cryopreserved with 5% DMSO (Galmes et al., 2007).  
In a pediatric setting, Curcoy and colleagues reported successful engraftment after short 
time storage at -80°C by using only 5% DMSO (Curcoy et al., 2002). It was also illustrated by 
in vitro studies that the numbers of both total and viable CD34+ cells were higher, CD34+ 
cells were less apoptotic and necrotic plus early hematopoietic progenitor cells were better 
preserved with 5 compared to 10% DMSO (Abrahamsen et al., 2002, 2004). As we reported 
from our clinical study, autografts stored in nitrogen gave similar hematopoietic recovery 
with hematopoietic stem cells cryopreserved either using 5 or 10% DMSO (Akkok et al., 
2008). These findings strongly suggest that cryopreservation of autologous stem cell grafts 
with 5 instead of 10% DMSO reduces the complication rate during stem cell infusion, 
without any adverse effect on time until hematopoietic reconstitution (Akkok et al., 2008; 
Games et al, 2007). 
5.4 Washing autografts to remove DMSO  
Washing autografts in order to remove as much DMSO as possible will also expectedly 
reduce the side effects associated with stem cell autograft infusion. However, there have 
been some conserns for this procedure based on the risk of CD34+ cell loss. Keeping this risk 
in mind, DMSO-depletion should be avoided when the CD34+ cell yield is barely 2 × 
106/kg. Some of the studies where DMSO depletion was utilized, included a large group of 
patients without bone marrow disease and may not be representative for the present use of 
autologous peripheral blood stem cell transplantation for hematological malignancies with 
diffuse infiltration of malignant cells throughout the bone marrow (Calmels et al., 2003; 
Rodriguez et al., 2005). These preclinical studies investigated grafts of highly selected 
patients who relapsed or died before autotransplantation could be done (Calmels et al., 
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2003; Rodriguez et al., 2005). Furthermore, Foïs et al. cryopreserved autografts with voluven 
+ DMSO 10% and not DMSO alone, and they did not include detailed analyses of 
engraftment and transfusion. This makes it difficult to evaluate the impact of DMSO-
depletion and compare with other studies (Foïs et al., 2007). Lemarie and colleagues used 
comprehensive automated washing to reach more than 20-fold reduction of DMSO-levels, 
whereas Syme and coworkers investigated patients with solid tumors and used a relatively 
extensive manual DMSO depletion (Lemarie et al., 2005; Syme et al., 2004).  
In the preclinical studies mentioned above (Calmels et al., 2003; Rodriguez et al., 2005), the 
researhers used a device; CytoMateTM, to perform the washing procedure with phosphate 
buffered saline (PBS) plus 5% Dextran-40, 5% ACD-A and 1-5% human serum albumin (HSA). 
While Calmels et al. achieved more than 96% elimination of DMSO and a mean recovery of 
viable total cells, CD34+ cells and lymphocyte subsets above 60%, Rodriguez et al. reported 
98% DMSO elimination and 103% CD34+ cell recovery. Foïs and co-authors used an 
automatic cell washer (COBE 2991) and diluted thawed autografts with a saline and acid 
citrate dextrose anticoagulant (ACD) solution. Washing procedure was repeated twice or 
three times before suspension in a glucose 5% solution (Foïs et al., 2007). Manual washing 
repeated three times was the method utilized by Syme and colleagues (Syme et al., 2004). 
They prepared a washing solution also with saline and citrate dextrose solution USP Formula 
A, and resuspended the final product again in the washing solution before infusion.  
Rowley et al. initiated a post-thaw DMSO-reduction study, where autografts cryopreserved 
with only 10% DMSO were thawed and diluted with 10% dextran-40 and 5% HSA (Rowley 
et al., 1999). Stem cell components were thereafter centrifuged to remove DMSO and 
resuspended in dextran and HSA before infusion. However, they had to stop the study for 
safety reasons due to severe infusion-related toxicity. Even though acute renal failure is a 
seldom complication associated with dextran use, dextran should probably not be the first 
choice in AL amyloidosis patients (Boldt, 2010), in whom dextran side effects like 
anaphylaxis may also bring additional risk. One of our studies described elsewhere, 
analysed a simple, one-step manual method for DMSO-depletion (Akkok et al., 2009). We 
diluted thawed autografts with a washing solution prepared by adding acid citrate dextrose 
(ACD) in saline. Following centrifugation the supernatant was removed and the autograft 
was resuspended with ACD-saline solution before infusion. By this means we achieved at 
least 6-fold reduction in the amount of infused DMSO, and the recovery data were 
comparable to the previous studies with regard to recovery of MNC and CD34+ cells (81.9 
and 77 percent, respectively) (Akkok et al., 2009).  
In the above mentioned study, we demonstrated that time until neutrophil engraftment was 
not affected by the DMSO-depletion (Akkok et al., 2009). Only three other earlier studies 
have investigated effects of DMSO-depletion on hematopoietic reconstitution, (Fois et al., 
2007; Lemarie et al., 2005; Syme et al., 2004) and two of them described comparable 
neutrophil engraftment following DMSO-removal (Lemarie et al., 2005; Syme et al., 2004). 
Syme and colleagues described 1 day shorter time until neutrophil engraftment for patients 
receiving DMSO-depleted grafts, but this difference reached only borderline significance 
(Syme et al., 2004). Thus, DMSO-depletion of stem cell grafts seems to have minimal effects 
on neutrophil engraftment. 
The significantly prolonged time until platelet engraftment for our patients receiving 
DMSO-depleted grafts was associated with a predictable increase in the number of platelet 
transfusions (Akkok et al., 2009). Lemarie et al. also described a slightly increased time until 
platelet engraftment for their patients, but the difference did not reach statistical significance 
(Lemarie et al. Transfusion 2005). In contrast, Syme et al. could not detect any effect of 
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DMSO-depletion on platelet engraftment time or platelet transfusion requirements (Syme et 
al., 2004). Taken together these results suggest that DMSO-depletion has relatively minor 
effects on platelet reconstitution.  
Finally, both our group and others have shown that washing out DMSO, either manually or 
with an automated device, is associated with fewer adverse effects (Akkok et al., 2009; Fois 
et al., 2007; Lemarie et al. Transfusion 2005). However, DMSO is probably not the only 
reason of adverse effects; factors like patient’s age (i.e. the higher the age the higher the 
frequency of adverse effects) and the content of infused non-mononuclear cells >0.5 x 
10(8)/kg have been reported, yet for non-cardiovascular adverse effects (Milone et al., 2007). 
Despite a significant reduction, both Lemarie et al. and Foïs et al. reported adverse effects in 
approximately 20 percent of patients after automated DMSO-depletion, which is very 
similar to our result (Akkok et al., 2009; Fois et al., 2007; Lemarie et al. Transfusion 2005). 
However, since the washing procedure will also reduce the number of neutrophils and the 
levels of a wide range of platelet- and leukocyte-derived soluble mediators (e.g. cytokines, 
soluble adhesion molecules, intracellular mediators), this reduction may also influence the 
frequencies of adverse events. It is important that DMSO-depletion procedures are effective; 
i.e. a meaningful DMSO-removal can be achieved, the procedure is not very time-
consuming and will not result in critical CD34+ cell loss. 
6. Conclusion 
Autologous stem cell transplantation has an important place in the management of primary 
amyloidosis patients. However, treatment-related mortality is very high especially in 
patients with cardiac amyloidosis compared with other hematologic disorders. Therefore, 
this therapeutic option can only be offered to one fourth of the patients. It may be assumed 
that underdiagnosed cardiac involvement may bring an additional risk for this patient 
group. The role of DMSO (used for cryopreservation of the autografts) in early treatment-
related mortality is undecided. Nevertheless,  it is shown that reduction of DMSO before 
stem cell infusion reduces adverse effects without essential disturbance of hematopoietic 
reconstitution, we therefore recommend cryopreservation with 5% DMSO in addition to 
removal of DMSO before stem cell infusion, whenever patients with primary amyloidosis 
have adequate yield of CD34+ cells in their autografts.  
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Çig ̆dem Akalin Akko ̈k and Øystein Bruserud (2011). Autologous Stem Cell Transplantation in the Treatment of
Amyloidosis – Can Manipulation of the Autograft Reduce Treatment-Related Toxicity?, Amyloidosis - An Insight
to Disease of Systems and Novel Therapies, Dr. Işıl Adadan Güvenç (Ed.), ISBN: 978-953-307-795-6, InTech,
Available from: http://www.intechopen.com/books/amyloidosis-an-insight-to-disease-of-systems-and-novel-
therapies/autologous-stem-cell-transplantation-in-the-treatment-of-amyloidosis-can-manipulation-of-the-
autogra
© 2011 The Author(s). Licensee IntechOpen. This is an open access article
distributed under the terms of the Creative Commons Attribution 3.0
License, which permits unrestricted use, distribution, and reproduction in
any medium, provided the original work is properly cited.
